(株)ミズホメディーの貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証STD | 医薬品 | 4595/ - | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2023/03/24 | 日証協 | 218,500株 | -7.1% | 5,470株 | -96.15% | 371,287株 | -4.75% | 78,305株 | -56.28% |
2023/03/17 | 日証協 | 235,200株 | +102.24% | 142,200株 | +1445.65% | 389,786株 | +4.01% | 179,109株 | +16.67% |
2023/03/10 | 日証協 | 116,300株 | -18.53% | 9,200株 | 0% | 374,759株 | -1.55% | 153,520株 | +5.19% |
2023/03/03 | 日証協 | 142,760株 | -6.67% | 0株 | -100% | 380,655株 | -5.66% | 145,946株 | +95.61% |
2023/02/24 | 日証協 | 152,960株 | -8.93% | 800株 | -96.6% | 403,500株 | +9.77% | 74,612株 | +46.67% |
2023/02/17 | 日証協 | 167,960株 | -26.55% | 23,500株 | +312.28% | 367,584株 | -10.33% | 50,871株 | +112.37% |
2023/02/10 | 日証協 | 228,660株 | -2.93% | 5,700株 | 0% | 409,951株 | +1.35% | 23,954株 | -66.78% |
2023/02/03 | 日証協 | 235,560株 | -0.25% | 0株 | -100% | 404,497株 | +0.58% | 72,115株 | -52.38% |
2023/01/27 | 日証協 | 236,160株 | -9.75% | 10,300株 | -56.9% | 402,174株 | +0.46% | 151,432株 | +64.22% |
2023/01/20 | 日証協 | 261,660株 | -0.3% | 23,900株 | +16.02% | 400,346株 | -0.57% | 92,213株 | +220.08% |
2023/01/13 | 日証協 | 262,460株 | +0.54% | 20,600株 | +24.1% | 402,645株 | +1.62% | 28,809株 | -45.25% |
2023/01/06 | 日証協 | 261,060株 | +5.75% | 16,600株 | -73.75% | 396,238株 | +72.9% | 52,616株 | -78.37% |
2022/12/30 | 日証協 | 246,870株 | +18.86% | 63,250株 | +213.12% | 229,169株 | -21.05% | 243,283株 | +209.18% |
2022/12/23 | 日証協 | 207,700株 | -22.5% | 20,200株 | -78.71% | 290,253株 | -28.24% | 78,686株 | -18.48% |
2022/12/16 | 日証協 | 268,000株 | +43.55% | 94,900株 | +1760.78% | 404,456株 | -1.08% | 96,522株 | +5.01% |
2022/12/09 | 日証協 | 186,700株 | +1.08% | 5,100株 | -10.53% | 408,863株 | -4.84% | 91,913株 | +265.31% |
2022/12/02 | 日証協 | 184,700株 | -1.02% | 5,700株 | -81% | 429,655株 | +7.48% | 25,160株 | -75.87% |
2022/11/18 | 日証協 | 170,100株 | +33.73% | 198,800株 | +9999.99% | 411,276株 | -22.25% | 86,124株 | +95.27% |
2022/11/11 | 日証協 | 127,200株 | -8.13% | 1,960株 | -95.69% | 528,969株 | +2.3% | 44,104株 | +228.94% |
※株式分割は考慮していませんのでご注意ください。
Page Top